Galvin is a professor of clinical biomedical science and associate dean for clinical research in the Charles E. Schmidt College of Medicine at Florida Atlantic University, and has a joint appointment as a professor in FAU's Christine E. Lynn College of Nursing.He also serves as director of the Toby and Leon Cooperman Center for Memory Disorders and Alzheimer's disease at the Marcus Neuroscience Institute at Boca Raton Regional Hospital.Previously, he held faculty positions at Washington University in St. Louis and at Hahnemann University in Philadelphia.He has done cross-cultural validation of dementia screening methods in comparison with Gold Standard clinical evaluations and biomarker assays.Dr. Galvin has published over 200 original scientific papers, three textbooks, and directed over 50 clinical trials for dementia treatments.He also has developed the Quick Dementia Rating System, which uses an evidence-based methodology to validly and reliably differentiate individuals with and without dementia.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Comprehensive Center for Brain Health
The study, published in Neurology ®, the medical journal of the American Academy of Neurology, reveals that costs associated with FTD are twice that of Alzheimer's disease . The researchers also found that costs for FTD were greater in the U.S. than in studies originating in other countries and the implications for patients and their caregivers are dire. "Frontotemporal degeneration is associated with substantial direct and indirect costs, diminished quality of life, and increased caregiver burden," said James E. Galvin, M.D., M.P.H., lead author, associate dean for clinical research in FAU's Charles E. Schmidt College of Medicine, and a leading international expert on AD, Lewy Body Dementia, and FTD. For the study and to quantify the socioeconomic burden of this disease, the researchers conducted a web-based survey to characterize the patient and caregiver experience with FTD-related resource use, health-related quality of life, and per-patient annual costs.
A recent study — the results of which have been published in the journal Clinical Interventions in Aging — has found that sarcopenia and obesity can heighten the risk of cognitive function impairments later in life. "Sarcopenia," explains senior study author Dr. James Galvin, "has been linked to global cognitive impairment and dysfunction in specific cognitive skills including memory, speed, and executive functions." " Understanding the mechanisms through which this syndrome may affect cognition is important as it may inform efforts to prevent cognitive decline in later life by targeting at-risk groups with an imbalance between lean and fat mass." To establish whether or not there was a link between sarcopenic obesity — that is, the presence of excess body fat in conjunction with muscle mass loss — and cognitive decline, the team assessed participants' performance on tests evaluating cognitive function, including the Montreal Cognitive Assessment and animal-naming exercises.